Clinical Trials Logo

Relapsed/Refractory Lymphoma clinical trials

View clinical trials related to Relapsed/Refractory Lymphoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05713110 Recruiting - Clinical trials for Relapsed/Refractory Lymphoma

A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma

Start date: February 13, 2023
Phase: Phase 2
Study type: Interventional

A phase II clinical study of tazemetostat combined with HMPL-689 in patients with R/R lymphoma. The study includes 2 phases: dose escalation phase (phase IIa) and expansion phase (phase IIb).

NCT ID: NCT05400876 Recruiting - Clinical trials for Relapsed/Refractory Lymphoma

To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma

Start date: June 9, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a two-phase, open-label Phase Ib clinical trial to evaluate the safety and efficacy of TQB2618 injection combined with Penpulimab in patients with relapsed and refractory lymphoma

NCT ID: NCT05189093 Recruiting - Clinical trials for Relapsed/Refractory Lymphoma

Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma

Start date: December 31, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a multi-center, open, single-arm phase I/II clinical study to evaluate the recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection in Chinese patients with relapsed/refractory lymphoma .